These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15449312)

  • 1. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
    Di Agostino S; Strano S; Emiliozzi V; Zerbini V; Mottolese M; Sacchi A; Blandino G; Piaggio G
    Cancer Cell; 2006 Sep; 10(3):191-202. PubMed ID: 16959611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
    Thomas S; Reisman D
    Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
    Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
    Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
    Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ANKRD11 as a p53 coactivator.
    Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
    J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
    Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
    Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 gain of function: the NF-Y connection.
    Peart MJ; Prives C
    Cancer Cell; 2006 Sep; 10(3):173-4. PubMed ID: 16959607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
    Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
    Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
    Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.
    Buganim Y; Kalo E; Brosh R; Besserglick H; Nachmany I; Rais Y; Stambolsky P; Tang X; Milyavsky M; Shats I; Kalis M; Goldfinger N; Rotter V
    Cancer Res; 2006 Nov; 66(22):10750-9. PubMed ID: 17108111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect of mutant and wild-type p53 on global gene expression.
    O'Farrell TJ; Ghosh P; Dobashi N; Sasaki CY; Longo DL
    Cancer Res; 2004 Nov; 64(22):8199-207. PubMed ID: 15548685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
    Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
    Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.